Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.248
Sell
RSI(14)
42.546
Neutral
STOCH(KDJ)(9,3,3)
26.688
Sell
ATR(14)
1.502
Low Volatility
CCI(14)
-103.135
Sell
Williams %R
90.750
Oversold
TRIX(12,20)
0.007
Sell
StochRSI(14)
0.000
Sell
Search
Alumis Inc
ALMSAdd to Watchlist
22.870USD
-1.760-7.15%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
2.91BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Alumis Inc
Currency: USD Updated: 2026-05-15Key Insights
Alumis Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 89 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 39.40.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alumis Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Alumis Inc Highlights
StrengthsRisks
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
Growing
The company is in a growing phase, with the latest annual income totaling USD 24.05M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 24.05M.
Undervalued
The company’s latest PE is -12.86, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 100.94M shares, increasing 17.49% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.61K shares of this stock.
Analyst Rating
Based on
11
analysts
Strong Buy
Current Rating
39.400
Target Price
+59.97%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Alumis Inc is 5.76, ranking 314 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.
Score
Financials
6.40
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.67
Operational Efficiency
2.84
Growth Potential
4.82
Shareholder Returns
7.08
Alumis Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Alumis Inc is 7.74, ranking 81 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -12.86, which is -96.53% below the recent high of -0.45 and -7.70% above the recent low of -13.85.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 89/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Alumis Inc is 9.09, ranking 14 out of 382 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 25.00 and a low of 14.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
11
analysts
Strong Buy
Current Rating
39.400
Target Price
+59.97%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Alumis Inc
ALMS
11
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Alumis Inc is 6.70, ranking 183 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 26.62 and the support level at 20.81, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
23.906
Sell
MA10
24.383
Sell
MA20
24.593
Sell
MA50
24.427
Sell
MA100
23.705
Sell
MA200
14.656
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Alumis Inc is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 82.61%, representing a quarter-over-quarter increase of 0.78%. The largest institutional shareholder is PRFDX, holding a total of 1.26M shares, representing 1.02% of shares outstanding, with 51035.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Alumis Inc is 1.69, ranking 278 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+32.59%
240-Day Volatility
+129.76%
Return
Best Daily Return
60 days
+9.01%
120 days
+95.31%
5 years
--
Worst Daily Return
60 days
-18.51%
120 days
-18.51%
5 years
--
Sharpe Ratio
60 days
-0.68
120 days
+2.19
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+32.59%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
+18.26
3 years
--
5 years
--
Skewness
240 days
+7.77
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+129.76%
5 years
--
Standardised True Range
240 days
+4.18%
5 years
--
Downside Risk-Adjusted Return
120 days
+698.89%
240 days
+698.89%
Maximum Daily Upside Volatility
60 days
+53.57%
Maximum Daily Downside Volatility
60 days
+57.18%
Liquidity
Average Turnover Rate
60 days
+1.32%
120 days
+2.12%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
Alumis Inc
ALMS
6.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
